ZIOPHARM Oncology Inc (NASDAQ:ZIOP) was the recipient of a large drop in short interest in November. As of November 15th, there was short interest totalling 34,003,445 shares, a drop of 3.9% from the October 31st total of 35,366,556 shares. Based on an average daily volume of 2,066,897 shares, the short-interest ratio is currently 16.5 days. Approximately 26.7% of the shares of the stock are sold short.

Several equities analysts have weighed in on the company. ValuEngine downgraded ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. BidaskClub raised ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research report on Tuesday, August 8th. HC Wainwright set a $10.00 price target on ZIOPHARM Oncology and gave the stock a “buy” rating in a research report on Tuesday, August 1st. Finally, Zacks Investment Research raised ZIOPHARM Oncology from a “hold” rating to a “buy” rating and set a $5.25 price target for the company in a research report on Friday, November 10th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $12.58.

ZIOPHARM Oncology (NASDAQ:ZIOP) opened at $4.35 on Tuesday. ZIOPHARM Oncology has a 1 year low of $4.03 and a 1 year high of $7.88.

ZIOPHARM Oncology (NASDAQ:ZIOP) last released its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.13) earnings per share for the quarter, hitting the consensus estimate of ($0.13). The company had revenue of $1.60 million for the quarter, compared to analysts’ expectations of $1.66 million. The business’s quarterly revenue was up .0% on a year-over-year basis. During the same period in the previous year, the business posted ($0.11) EPS. sell-side analysts anticipate that ZIOPHARM Oncology will post -0.54 EPS for the current year.

In other news, CEO Laurence James Neil Cooper acquired 6,440 shares of the company’s stock in a transaction that occurred on Wednesday, November 8th. The stock was purchased at an average cost of $4.68 per share, with a total value of $30,139.20. Following the purchase, the chief executive officer now directly owns 1,083,731 shares of the company’s stock, valued at approximately $5,071,861.08. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 10.40% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in ZIOP. Chevy Chase Trust Holdings Inc. acquired a new stake in shares of ZIOPHARM Oncology during the third quarter worth $104,000. Amalgamated Bank boosted its holdings in shares of ZIOPHARM Oncology by 12.9% during the second quarter. Amalgamated Bank now owns 16,807 shares of the biotechnology company’s stock worth $105,000 after purchasing an additional 1,924 shares during the last quarter. BB&T Securities LLC acquired a new stake in shares of ZIOPHARM Oncology during the second quarter worth $112,000. Oppenheimer & Co. Inc. boosted its holdings in shares of ZIOPHARM Oncology by 50.0% during the second quarter. Oppenheimer & Co. Inc. now owns 18,000 shares of the biotechnology company’s stock worth $112,000 after purchasing an additional 6,000 shares during the last quarter. Finally, Adell Harriman & Carpenter Inc. acquired a new stake in shares of ZIOPHARM Oncology during the third quarter worth $141,000. 41.90% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Short Interest in ZIOPHARM Oncology Inc (ZIOP) Decreases By 3.9%” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/11/28/short-interest-in-ziopharm-oncology-inc-ziop-decreases-by-3-9.html.

ZIOPHARM Oncology Company Profile

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

Receive News & Stock Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related stocks with our FREE daily email newsletter.